- Trials with a EudraCT protocol (64)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
64 result(s) found for: Hematuria.
Displaying page 1 of 4.
EudraCT Number: 2007-004518-15 | Sponsor Protocol Number: 28113 | Start Date*: 2008-08-05 | |||||||||||
Sponsor Name:Merck Serono International | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy | |||||||||||||
Medical condition: Lupus nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002716-27 | Sponsor Protocol Number: ALN-CC5-005 | Start Date*: 2019-06-11 |
Sponsor Name:Alnylam Pharmaceuticals Inc | ||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy | ||
Medical condition: Immunoglobulin A nephropathy (IgAN) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) SE (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-000729-13 | Sponsor Protocol Number: 2020_0068 | Start Date*: 2021-01-21 |
Sponsor Name:Hôpital Foch | ||
Full Title: Evaluation of Glucocorticoids plus Rituximab compared to Glucocorticoids plus Placebo for the treatment of patients with newly-diagnosed or relapsing IgA vasculitis : A prospective, randomized, con... | ||
Medical condition: Patients with a diagnosis of IgAV according to Chapel Hill Consensus Conference definitions. Patients will require having a biopsy-proven diagnosis of IgAV. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004394-10 | Sponsor Protocol Number: ACT16248 | Start Date*: 2020-06-30 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administe... | |||||||||||||
Medical condition: Congenital, hereditary and neonatal diseases | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002610-37 | Sponsor Protocol Number: SIREPNA/05 | Start Date*: 2005-12-05 |
Sponsor Name:NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE) | ||
Full Title: PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS. Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas d... | ||
Medical condition: To test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004082-39 | Sponsor Protocol Number: GOOD-IDES-01 | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Linköping University | |||||||||||||
Full Title: An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES | |||||||||||||
Medical condition: Anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004852-62 | Sponsor Protocol Number: FARM7KWBZ4 | Start Date*: 2009-02-09 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI | ||||||||||||||||||
Full Title: Safety and clinical efficacy of abetimus sodium (LJP-394) in prevention of renal flares in patients with systemic lupus erythematosus and a history of renal disease. | ||||||||||||||||||
Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024300-10 | Sponsor Protocol Number: EARLY_PRO-TECT_ALPORT | Start Date*: 2012-02-27 | |||||||||||
Sponsor Name:University Medical Center Göttingen | |||||||||||||
Full Title: Early prospective therapy trial to delay renal failure in children with Alport syndrome. | |||||||||||||
Medical condition: Alport's syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000722-26 | Sponsor Protocol Number: AVM-003-HC | Start Date*: 2021-01-11 | |||||||||||
Sponsor Name:AlloVir, Inc. | |||||||||||||
Full Title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Trans... | |||||||||||||
Medical condition: Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004395-22 | Sponsor Protocol Number: 402-C-1603 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:Reata Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome | |||||||||||||
Medical condition: Alport Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004192-13 | Sponsor Protocol Number: R3R01-ASFSGS-201 | Start Date*: 2022-08-12 | ||||||||||||||||
Sponsor Name:River 3 Renal, Corporation | ||||||||||||||||||
Full Title: A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and... | ||||||||||||||||||
Medical condition: Alport Syndrome (AS) and Primary Steroid-Resistent Focal Segmental Glomerulosclerosis (FSGS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001222-15 | Sponsor Protocol Number: CL002_168 | Start Date*: 2011-07-20 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Bac... | |||||||||||||
Medical condition: Non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV) with mild-to-moderate renal involvement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) CZ (Completed) SE (Completed) DE (Completed) NL (Completed) HU (Completed) PL (Completed) AT (Completed) IE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000891-27 | Sponsor Protocol Number: CLNP023X2203 | Start Date*: 2017-11-21 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients | |||||||||||||
Medical condition: Primary IgA Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) CZ (Completed) HU (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022988-35 | Sponsor Protocol Number: FIBHGM-ECNC013-2010 | Start Date*: 2011-06-27 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Gregorio Marañón | |||||||||||||
Full Title: TRATAMIENTO DE LA CISTITIS HEMORRÁGICA SEVERA POST-TRASPLANTE ALOGÉNICO CON CÉLULAS MESENQUIMALES | |||||||||||||
Medical condition: Cistitis Hemorragica Servera Post-transplante | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005081-60 | Sponsor Protocol Number: RENAL-AAD | Start Date*: 2017-04-21 |
Sponsor Name:Jose Luis Calleja Panero | ||
Full Title: MULTICENTER CLINICAL TRIAL TO DETERMINE THE INFLUENCE OF TREATMENT WITH DIRECT ANTIVIRAL AGENTS IN THE GLOMERULAR AND TUBULAR FUNCTION OF PATIENTS WITH CHRONIC HCV HEPATITIS | ||
Medical condition: Hepatitis C | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005856-32 | Sponsor Protocol Number: RITULUP | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:Fundación Progreso y Salud | |||||||||||||
Full Title: Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy resistant to conventional treatment | |||||||||||||
Medical condition: Long-term relapse after treatment of lupus nephritis (LN) resistant to conventional treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001920-36 | Sponsor Protocol Number: NIMAO/2018-01/JF-01 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:CHU de NIMES | |||||||||||||
Full Title: Phase II a study to evaluate the safety, tolerability, distribution and dose effect of neoadjuvant doxorubicin arterial embolization in patients with prostate cancer at high risk of recurrence befo... | |||||||||||||
Medical condition: patients with high-risk prostate cancer with a Gleason score of 9-10 on biopsy,multimodal treatment radical prostatectomy validated in CPR, managed in Hospital of Nîmes. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006491-38 | Sponsor Protocol Number: N06SUN | Start Date*: 2007-04-16 |
Sponsor Name:NKI-AVL | ||
Full Title: Sunitinib prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ | ||
Medical condition: metastatic renal cell carcinoma and the primary tumor in situ | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002240-14 | Sponsor Protocol Number: TARIBO | Start Date*: 2015-09-29 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Targeted Therapy with or without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery | |||||||||||||
Medical condition: Patients affected by non treated metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003740-39 | Sponsor Protocol Number: URO-CHUAC-BPSat-001. | Start Date*: 2016-04-12 | |||||||||||
Sponsor Name:Jose Luis Ponce Díaz-Reixa | |||||||||||||
Full Title: Open randomized clinical trial to examine individual pain tolerance in the use of two anesthetic techniques to perform saturation prostate biopsy . | |||||||||||||
Medical condition: Prostate biopsy anesthesia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
